Browse studies
Find your next paid study
16 recruiting studies matching your filters
Observational
NearWave Optical Molecular Monitoring for Predicting Complete Pathological Response (pCR) to Neoadjuvant Chemotherapy (NAC) in Breast Cancer Patients
The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pa…
Breast CancerHER2-positive Breast CancerTNBC - Triple-Negative Breast Cancer+2 more
Estimated
~$10 – $6,250
Indiana UniversityNCT06744465
Phase 2
IIT2024-02-SHIAO-ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
Open label, single-arm, prospective therapeutic trial. Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progress…
TNBC - Triple-Negative Breast CancerBreast Cancer
Estimated
~$10 – $7,500
Stephen ShiaoNCT07015853
Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided te…
TNBC - Triple-Negative Breast CancerMinimal Residual Disease
Estimated
~$10 – $1,050
Personalis Inc.NCT06230185
Phase 2
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early Stage Triple Negative Breast Cancer
This is a single arm phase II trial combination of ivonescimab and carbo-docetaxel every 3 weeks for 6 cycles in patients with early-stage triple negative brea…
TNBCTNBC - Triple-Negative Breast CancerEarly Stage Triple-Negative Breast Carcinoma
Estimated
~$10 – $6,250
Cedars-Sinai Medical CenterNCT07017673